➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
Johnson and Johnson
Colorcon
McKesson

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIGALASTAT HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Migalastat Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00214500 A Study of AT1001 in Patients With Fabry Disease Completed Amicus Therapeutics Phase 2 2005-09-01 The purpose of this study is to determine whether AT1001 (migalastat hydrochloride) is safe and effective in patients with Fabry disease.
NCT00283933 A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease Completed Amicus Therapeutics Phase 2 2006-01-01 The purpose of this study is to collect information on the safety of AT1001 (migalastat hydrochloride) and how AT1001 works in patients with Fabry disease.
NCT00283959 A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease Completed Amicus Therapeutics Phase 2 2006-03-01 The purpose of this study is to collect information on the safety of AT1001 (migalastat hydrochloride) and how AT1001 works in patients with Fabry disease.
NCT00304512 A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease Completed Amicus Therapeutics Phase 2 2006-05-01 The purpose of this study is to determine whether AT1001 (migalastat hydrochloride) is safe and effective in female patients with Fabry disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Migalastat Hydrochloride

Condition Name

Condition Name for Migalastat Hydrochloride
Intervention Trials
Fabry Disease 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Migalastat Hydrochloride
Intervention Trials
Fabry Disease 16
Renal Insufficiency 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Migalastat Hydrochloride

Trials by Country

Trials by Country for Migalastat Hydrochloride
Location Trials
United States 56
Australia 9
United Kingdom 7
Canada 6
Spain 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Migalastat Hydrochloride
Location Trials
Georgia 8
New York 6
Texas 6
Pennsylvania 5
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Migalastat Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Migalastat Hydrochloride
Clinical Trial Phase Trials
Phase 3 7
Phase 2 4
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Migalastat Hydrochloride
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 3
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Migalastat Hydrochloride

Sponsor Name

Sponsor Name for Migalastat Hydrochloride
Sponsor Trials
Amicus Therapeutics 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Migalastat Hydrochloride
Sponsor Trials
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Moodys
Harvard Business School
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.